X4 Pharma completes reverse merger with Arsanis

X4 Pharmaceuticals, a clinical-stage biopharma company focused on treatments of rare diseases, today announced the completion of its merger with Arsanis, effective as of March 13, 2019.

Shares of the new X4 are set to begin trading on the Nasdaq exchange Thursday under the stock symbol “XFOR.”

The holders of shares of X4 capital stock outstanding immediately prior to the merger received 0.5702 shares of Arsanis common stock in exchange for each share of X4 capital stock in the merger. On March 13, 2019, Arsanis is effecting a six-for-one reverse stock split.